Status:
TERMINATED
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Advanced Solid Tumors
Metastatic Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastat...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
- Progressed after at least 1 line of treatment and no more than 3 lines of treatment
- At least one measurable lesion as defined by RECIST version 1.1
- ECOG Performance Status 0 or 1
- Adequate Bone Marrow Function
- Adequate Renal Function
- Adequate Liver Function
- Resolved acute effects of any prior therapy
Exclusion
- Known active uncontrolled or symptomatic CNS metastases.
- Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
- Active, uncontrolled infection, including COVID-19
- Known or suspected hypersensitivity to PF-06939999
- Inability to consume or absorb study drug
Key Trial Info
Start Date :
March 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2022
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03854227
Start Date
March 14 2019
End Date
April 27 2022
Last Update
January 13 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale Healthcare Hospitals d/b/a HonorHealth
Scottsdale, Arizona, United States, 85258
2
Virginia G. Piper Cancer Pharmacy
Scottsdale, Arizona, United States, 85258
3
Keck Hospital of USC
Los Angeles, California, United States, 90033
4
LAC + USC Medical Center
Los Angeles, California, United States, 90033